CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004
to standard of care Sirolimus (SIR)-based immune suppression.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute